Benign prostatic hyperplasia: natural history, endocrine pathogenesis, and medical treatment with finasteride.
Sherwood
L M
LM
U.S. Human Health, Merck & Co., Inc., West Point, PA 19486-0004, USA.
D000293:Adolescent; D000328:Adult; D000368:Aged; D013196:Dihydrotestosterone / Q000097:blood; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D018120:Finasteride / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology; D012307:Risk Factors; D014555:Urination Disorders / Q000209:etiology
D004791:Enzyme Inhibitors; D013196:Dihydrotestosterone; D018120:Finasteride; D017430:Prostate-Specific Antigen